Biogen Idec, Inc. v. GlaxoSmithKline LLC (Fed. Cir. 2013)

by McDonnell Boehnen Hulbert & Berghoff LLP

Yesterday, in Biogen Idec, Inc. v. GlaxoSmithKline LLC, the Federal Circuit affirmed the determination by the District Court for the Southern District of California that the claim term "anti-CD20 antibody" as used in U.S. Patent No. 7,682,612 was limited by prosecution history estoppel.  The '612 patent is directed to the treatment of hematologic malignancies associated with circulating tumor cells using anti-CD20 antibodies.  Representative claim 1 recites:

1.  A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the method does not include treatment with a radiolabeled anti-CD20 antibody.

Protein_MS4A1_PDB_1S8BAs the majority opinion notes, it was initially believed that only one large loop (epitope) of the CD20 antigen (at right) was exposed on the surface of cancerous B cells, and therefore, that there was only one suitable target for the anti-CD20 antibody.  However, after Biogen filed the application that issued as the '612 patent, other researchers discovered that the CD20 antigen had a second small loop to which certain anti-CD20 antibodies could bind.

During the prosecution of the application that issued as the '612 patent, the examiner rejected the claims because the specification did not provide enablement commensurate with the scope of the claimed invention, which the examiner contended included "any and all anti-CD20 antibodies, no matter the specificity or affinity for the specific epitope on the circulating tumor cells."  The examiner acknowledged that the specification was enabling for Biogen's chimeric gamma 1 anti-human CD20 antibody, Rituxan® (rituximab), but was silent concerning the specificity and affinity that would be necessary for other anti-CD20 antibodies.  In response to the rejection, Biogen stated that:

[E]ven though antibodies directed to the same antigen might have different affinities and functional characteristics, one of skill in the art could readily identify an antibody that binds to CD20 with similar affinity and specificity as does RITUXAN® using techniques that are well known in the art.  . . .  With that knowledge in hand, the skilled artisan could readily produce anti-CD20 antibodies using similar techniques, and screen such antibodies for those having an affinity and functional activity similar to RITUXAN®.

The examiner then withdrew the rejection and allowed the application.

GlaxoSmithKline - GSKIn March 2010, Biogen filed suit against GlaxoSmithKline, asserting that GSK's anti-CD20 antibody Arzerra® (ofatumumab) infringed claims 1-4, 6, 8-10, 14-17, 20-22, and 58-60 of the '612 patent.  In contrast with Rituxan®, Arzerra® binds to the second small loop of the CD20 antigen, has a much greater affinity for the CD20 antigen, and is a fully human antibody.  The District Court conducted a Markman hearing to construe three terms, including the term "anti-CD20 antibody."  The District Court rejected Biogen's broad construction of "an antibody that binds to a cell surface CD20 antigen," and instead adopted GSK's construction "rituximab and antibodies that bind to the same epitope of the CD20 antigen with similar affinity and specificity as rituximab."  In adopting the latter construction, the District Court noted that prosecution history disclaimer applied because Biogen had limited the term to overcome the examiner's enablement rejection.  Following this construction, Biogen stipulated to noninfringement and appealed the District Court's construction to the Federal Circuit.

Biogen IdecWriting for the majority, Judge Reyna notes that because neither the claims nor the specification compelled a construction that was contrary to the one offered by Biogen, the question before the Court was whether statements in the prosecution history were sufficient to overcome the heavy presumption that the term "anti-CD20 antibody" carries its full ordinary and customary meaning.  The majority concludes that Biogen's statements during prosecution were sufficient.  In particular, the majority observes that:

[R]ather than challenging the examiner's understanding of the crucial terms, the applicants argued that the specification was enabling for anti-CD20 antibodies with similar affinity and specificity as Rituxan®.  Indeed, the applicants conceded that other "antibodies directed to the same antigen [i.e., CD20] might have different affinities and functional characteristics," and limited their claims to antibodies similar to Rituxan® nonetheless.  . . .  [I]t is clear that they were limiting their invention to what the examiner believed they enabled: antibodies that have a similar specificity and affinity for the specific epitope to which Rituxan® binds.

The majority also found both of Biogen's arguments regarding why the plain and ordinary meaning of the term should control to be unpersuasive.  First, in response to Biogen's argument of claim differentiation (that claim 1 broadly covers any and all anti-CD20 antibodies and several dependent claims are directed to specific types of antibodies, i.e., chimeric, rituximab, humanized, and human), the majority counters that "[o]ur cases make clear . . . that where found, prosecution history disclaimer can overcome the presumption of claim differentiation."  In response to Biogen's second argument that the '612 patent incorporates U.S. Patent No. 5,736,137, and that the '137 patent's broader definition of "anti-CD20 antibody" should control, the majority states that "[t]he problem with this argument is that the '137 patent expressly and uniquely defines 'anti-CD20 antibody' for use therein, that is, within the '137 patent."

Writing in dissent, Judge Plager states that "[b]ecause I do not find anywhere in the majority opinion or in the prosecution history that clear and unmistakable evidence of a disclaimer as required by our precedents, I cannot agree with the majority that such a disclaimer was made by Biogen during the prosecution of its application for the '612 patent."  Noting that "[t]he only dispute is whether the applicants disclaimed the plain meaning of 'anti-CD20 antibody' during prosecution," Judge Plager states that "[t]he majority purports to tease out of the prosecution history such a disclaimer."  The dissent continues:

Nowhere in the prosecution history did the applicants state that antibodies that bind to the same epitope on CD20 with similar affinity and specificity as RITUXAN® must be used, or that antibodies lacking those characteristics must not be used.  To the contrary, the applicants repeatedly made clear -- including in the same discussion as the allegedly disclaiming statement -- that because the invention was based on the discovery that anti-CD20 antibodies could treat CLL, the claimed methods were not limited to the use of any particular type anti-CD20 antibody.

"Because the district court's construction eviscerates the 'clear and unmistakable' requirement for prosecution disclaimer," Judge Plager states that he "cannot join the majority in affirming that erroneous construction."

Biogen Idec, Inc. v. GlaxoSmithKline LLC (Fed. Cir. 2013)
Panel: Circuit Judges Dyk, Plager, and Reyna
Opinion by Circuit Judge Reyna; dissenting opinion by Circuit Judge Plager


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.